Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Mentor, mother, activist, advocate, sister, survivor, researcher and Fred Hutch friend, Bridgette Hempstead died last month ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

The clinical nurse specialist in uro-oncology is undervalued and underdeveloped, according to a discussion paper on the role of this clinician.

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

For the fifth consecutive year, Congress has adjourned and allowed Medicare cuts,” said Bruce A. Scott, MD, president of the AMA.

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...